BeOne Medicines AG (ONC) News
Track canonical SquawkNews coverage tagged to ONC, BeOne Medicines AG. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
BeiGene Reports Q2 2026 Results: Full Earnings Call Transcript
BeiGene (NASDAQ: ONC ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transcripts, visit
LIVE | Sep 17, 2026, 01:43 PM UTC
H
BeOne Medicines wins U.S. FDA approval for TEVIMBRA-based regimen
BeOne Medicines announces U.S. FDA approval for a TEVIMBRA-based regimen for first-line HER2+ GEA.
EQUITY | Aug 25, 2026, 02:46 PM UTC
L
ONC Beats Estimates
ONC reports $1.7B revenue
EARNINGS | Aug 05, 2026, 10:11 AM UTC
L
BeOne Medicines Raises FY2026 Sales Guidance from $6.300B-$6.500B to $6.600B-$6.800B vs $6.479B Est
BeOne Medicines (NASDAQ: ONC ) raises FY2026 sales outlook from $6.300 billion-$6.500 billion to $6.600 billion-$6.800 billion vs $6.479 billion estimate.
EARNINGS | Aug 05, 2026, 10:00 AM UTC
L
Beone Medicines Insider Sold Shares Worth $44,626,424, According to a Recent SEC Filing
() -- John Oyler, Director, Chief Executive Officer, on July 14, 2026, sold 145,861 shares in Beone Medicines (ONC) for $44,626,424. Following the Form 4 filing with the SEC, Oyler has control over a total of 51,477,911
REGULATION | Jul 15, 2026, 08:11 AM UTC
L
Beone Medicines Insider Sold Shares Worth $18,256,808, According to a Recent SEC Filing
() -- John Oyler, Director, Chief Executive Officer, on July 10, 2026, sold 60,218 shares in Beone Medicines (ONC) for $18,256,808. Following the Form 4 filing with the SEC, Oyler has control over a total of 51,637,304 o
REGULATION | Jul 15, 2026, 08:11 AM UTC
L
BeOne Medicines treatment of pancreatic cancer granted orphan status
BeOne Medicines' MTA-cooperative PRMT5 inhibitor was granted FDA orphan designation as a treatment of pancreatic cancer, according to a post to the agency's website. Reference Link
EQUITY | Jul 09, 2026, 02:58 PM UTC
H
BeOne Medicines price target raised to $451 from $436 at RBC Capital
RBC Capital raised the firm's price target on BeOne Medicines to $451 from $436 and keeps an Outperform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has pi
RATES | Jul 07, 2026, 11:30 AM UTC
L
Curis Consents 6 Patients in Phase 2 Trial of Emavusertib in Chronic Lymphocytic Leukemia
() -- Curis (CRIS) said Monday it has consented the first six patients in a phase 2 study of emavusertib in chronic lymphocytic leukemia, or CLL, just days after opening 11 clinical sites for enrollment. The biotechnolog
EQUITY | Jul 06, 2026, 02:11 PM UTC
L
Citizens Reiterates Market Outperform on BeOne Medicines, Maintains $396 Price Target
Citizens analyst Reni J. Benjamin reiterates BeOne Medicines (NASDAQ: ONC ) with a Market Outperform and maintains $396 price target.
EQUITY | Jul 01, 2026, 01:43 PM UTC
H
BeOne Medicines Announces Topline Results From Its Phase 3 MANGROVE Study Of Foundational BTK Inhibitor Brukinsa Plus Rituximab In Adult Pat
BeOne Medicines Ltd. (NASDAQ: ONC, HKEX: 06160, SSE: 688235))), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK
EQUITY | Jun 30, 2026, 10:06 AM UTC